Evidence map›Paper›PMID 31104167›Full record

Trial reportCancer causes & control : CCC2019

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D

Chen Yuan, Lindsay Renfro, Pratibha B Ambadwar, Fang-Shu Ou, Howard L McLeod, Federico Innocenti, Jeffrey A Meyerhardt, Brian M Wolpin, Richard M Goldberg, Axel Grothey and 2 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003594 (A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum), which is not on this map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00003594 phase3completednot on this map

A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum

TypeinterventionalSponsorAlliance for Clinical Trials in OncologyRan1998 to 2004Enrolled1,691ConditionsColorectal CancerArmsirinotecan, fluorouracil, leucovorin calcium, oxaliplatin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Chen YuanDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. chen_yuan@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-0708-9648
Lindsay RenfroDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Pratibha B AmbadwarDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Fang-Shu OuAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Howard L McLeodDeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL, USA.
Federico InnocentiEshelman School of Pharmacy and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Brian M WolpinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Richard M GoldbergWest Virginia University Cancer Institute, Morgantown, WV, USA.
Axel GrotheyDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Charles S FuchsYale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA.
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Harvard University · USMayo Clinic · USMayo Clinic in Arizona · USMoffitt Cancer Center · USUniversity of North Carolina at Chapel Hill · USWest Virginia University · USYale Cancer Center · US

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
$6.6M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2M
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9M
NCTN Lead Academic Participating Sites ApplicationU10CA180838 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAREY, LISA A · 2014 to 2018
$2.8M
NCI NIH HHS R01 CA205406NCI NIH HHS U10 CA180790NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA233180NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

purposeThe relationships of genetic variation in the vitamin D pathway with circulating 25-hydroxyvitamin D

methodsAmong 535 patients participating in a randomized trial of chemotherapy for mCRC, we prospectively measured baseline plasma 25(OH)D and examined 124 tagging single-nucleotide polymorphisms (SNPs) within seven genes in the vitamin D pathway, including five SNPs associated with circulating 25(OH)D levels in previous genome-wide association studies (GWAS). We evaluated whether these SNPs were associated with plasma 25(OH)D levels and patient outcome (overall survival, time to progression, and tumor response), using linear, logistic, and Cox proportional hazards regression.

resultsWe observed a significant association between 25(OH)D levels and an additive genetic risk score determined by the five GWAS-identified SNPs (p = 0.0009). We did not observe any direct association between 25(OH)D-associated SNPs, individually or as a genetic risk score, and patient outcome. However, we found a significant interaction between 25(OH)D levels and rs12785878 genotype in DHCR7 on overall survival (p

conclusionGermline genetic variation in the vitamin D pathway informs baseline 25(OH)D levels among patients with mCRC. The association between 25(OH)D levels and overall survival may vary by DHCR7 genotype. ClinicalTrials.gov Identifier: NCT00003594 ( https://clinicaltrials.gov/ct2/show/NCT00003594 ).

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCalcifediolColorectal NeoplasmsFemaleGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideSurvival AnalysisVitaminsCalcifediolVitamins25-hydroxyvitamin D3Metastatic colorectal cancerSingle-nucleotide polymorphismsSurvival

Identifiers

PMID31104167
PMCPMC6639016
OpenAlexW2945684619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.